Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort (Fractyl Health)

Fractyl Health announced promising early results from the REVEAL-1 cohort of the REMAIN-1 study, showing weight maintenance one month after GLP-1 drug discontinuation and the Revita procedure. This aligns with prior findings and underscores Revita’s potential in addressing post-GLP-1 weight regain challenges. Strong enrollment progress highlights significant demand for alternatives to chronic GLP-1 therapies, with mid-point analysis expected in Q2 2025. Revita, a breakthrough device targeting gut-driven metabolic disease, represents a promising step toward durable weight maintenance solutions. Could this mark the start of a new era in obesity and diabetes care?